MedTrace Logo

Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR

NCT06015997 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-08-29

No results posted yet for this study

Summary

ATTR-cardiac amyloidosis (CA) is present in 4% to 16% of elderly patients with severe calcific aortic stenosis (AS). The reasons for this association are not fully known. It is hypothesized that an amyloidotic infiltration of the aortic valve acts as a trigger for the development of endothelial damage and subsequent calcification. Elderly patients undergoing TAVI will be evaluated for the presence of ATTR-CA in Jordan.

Conditions

  • ATTR Amyloidosis Wild Type
  • Severe Aortic Stenosis
  • Aortic Valve Stenosis
  • Middle East Studies

Sponsors & Collaborators

  • Jordan Collaborating Cardiology Group

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-09-30
Completion
2025-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015997 on ClinicalTrials.gov